Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05879068
PHASE2

A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC

Sponsor: Biotheus Inc.

View on ClinicalTrials.gov

Summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with paclitaxel as second line treatment for SCLC.

Official title: A Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Paclitaxel Injection as Second Line Treatment for Small Cell Lung Cancer(SCLC)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

99

Start Date

2022-05-27

Completion Date

2026-04-30

Last Updated

2024-12-18

Healthy Volunteers

No

Conditions

Interventions

DRUG

PM8002

IV infusion

DRUG

Paclitaxel

IV infusion

Locations (11)

Peking University Cancer Hospital

Beijing, China

Jilin Provincial Tumor Hospital

Changchun, China

Hunan Cancer Hospital

Changsha, China

Sichuan Provincial People's Hospital

Chengdu, China

Zhejiang Provincial People's Hospital

Hangzhou, China

Harbin Medical University Cancer Hospital

Harbin, China

Shandong Cancer Hospital

Jinan, China

The First Affiliated Hospital of Nanchang University

Nanchang, China

Shanghai Pulmonary Hospital

Shanghai, China

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, China

Henan Cancer Hospital

Zhengzhou, China